Articles

Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative. Read More ›

GRIFFIN Study: Daratumumab Deepens Responses Over Time

ASH 2019 – Multiple Myeloma

Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses. Read More ›

Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma

ASH 2019 – Multiple Myeloma

Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes. Read More ›

Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial

ASH 2019 – Multiple Myeloma

For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed. Read More ›

Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma

ASH 2019 – Multiple Myeloma

After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma. Read More ›

Benefit Shown for Daratumumab plus Carfilzomib + Dexamethasone

ASH 2019 – Multiple Myeloma

Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival. Read More ›

Study Moves CAR-T Therapy Forward in Myeloma

ASH 2019 – Multiple Myeloma

Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative. Read More ›

Articles

Page 75 of 143